Focused ultrasound for major depressive disorder

Focused ultrasound for major depressive disorder Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting 300 million people with a lifetime prevalence of 15%. Approximately one-third of all major depressive disorder patients fail to respond to currently established treatments based on medication and psychotherapy, thus falling into the category of Treatment-Resistant Depression (TRD) patients. In addition, 3 out of 4 patients in low and middle-income countries receive no treatment. Low-Intensity Focused Ultrasound (LIFU) is an emerging neuromodulation method for treating major depressive disorder which allows for non-invasive stimulation across the whole brain.